市场调查报告书
商品编码
1260686
电生理学市场——按产品、按适应症、最终用途和全球预测,2023-2032 年Electrophysiology Market - By Product, By Indication, By End-use & Global Forecast, 2023 - 2032 |
电生理学行业预计到 2032 年将实现巨大增长。
由于与生活方式相关的健康状况普遍存在,电生理学 (EP) 测试广受欢迎。 久坐不动的生活方式、过量饮酒和吸烟大大增加了心脏病的发病率。
此外,人口老龄化也是加重医疗负担的重要因素。 心力衰竭、心动过缓期间的心臟起搏、房颤和心肌梗死后的室性心律失常是需要心臟 EP 的一些健康状况。
在过去十年中,医疗保健领域的消融技术取得了重大进展,人们越来越努力设计针对心律失常的自动化单次注射治疗。 先进的 3D 绘图技术的发展以及人工智能和机器学习的使用将使心脏病的有效诊断和治疗成为可能。
2022 年 7 月,Stereotaxis 为其磁性介入消融导管“MAGiC”导管申请了 CE 标誌,该导管旨在藉助机器人导航支持微创手术。 GE Healthcare、Japan Lifeline、Medtronic、Siemens AG 和 Abbott Laboratories 等其他参与者正在引领机器人心臟消融手术的类似创新。
电生理学市场分为产品、适应症、最终用途和区域。
按产品划分,我们分为电生理诊断导管、电生理消融导管和电生理实验室设备。 到 2022 年,EP 消融导管部分的收入份额将超过 26 亿美元。 由于新兴国家人口老龄化,越来越多的慢性病患者预计将推动对 EP 消融导管的需求。
根据迹象,到 2032 年底,房扑电生理学市场份额预计将超过 17 亿美元。 心房扑动是由高血压等健康状况引起的心臟电系统变化引起的疾病。 根据世界卫生组织 (WHO) 的数据,在过去 30 年中,30-79 岁人群的高血压病例从 6.5 亿增加到 12.8 亿。
电生理学市场根据最终用途细分为医院、门诊手术中心、导管插入术/EP 实验室等。 到 2022 年,门诊手术中心部门的收入份额将超过 1.8 亿美元。 由于方便使用先进的医疗设施,患者越来越喜欢在门诊进行单日心血管手术。 我们的门诊手术中心还以实惠的价格提供一流的医疗保健服务。
到 2032 年底,亚太地区的电生理学市场预计将超过 39 亿美元。 增加公共和私人资金以支持心血管疾病意识将补充亚太地区的行业扩张。 中国和印度等亚太国家的医疗旅游正在快速增长,预计在预测期内将提供有利可图的商业前景。
The electrophysiology industry is anticipated to record tremendous growth by 2032. Electrophysiology (EP) tests have gained significant popularity due to the high prevalence of lifestyle-related health conditions. Due to sedentary lifestyles, excessive alcohol consumption, and tobacco smoking, the incidences of heart disease have increased considerably.
Furthermore, aging is a crucial factor in increasing the healthcare burden. Heart failure, cardiac pacing in case of bradycardia, atrial fibrillation, and ventricular arrhythmias post-myocardial infarction are some of the health conditions that require cardiac EP.
Over the last decade, the healthcare sector has witnessed substantial advancements in ablation technology, with increasing efforts to design automated, single-shot treatments for cardiac arrhythmias. The development of sophisticated 3D mapping techniques and the use of AI and machine learning will enable efficient diagnosis and treatment of cardiac diseases.
In July 2022, Stereotaxis applied for CE Marking of its MAGiC catheter, a magnetic interventional ablation catheter designed to support minimally invasive surgeries with the help of robotic navigation. Similar innovations in robotics-based cardiac ablation procedures are being led by other players such as GE Healthcare, Japan Lifeline, Medtronic, Siemens AG, and Abbott Laboratories among others.
The electrophysiology market is classified into product, indication, end-use, and region.
Based on product, the industry is bifurcated into EP diagnostic catheters, EP ablation catheters, and EP laboratory devices. The EP ablation catheters segment accounted for more than USD 2.6 billion in revenue share in 2022. The increasing geriatric population in developing countries contributing to a large patient pool of chronic diseases will propel the demand for EP ablation catheters.
By indication, the electrophysiology market share from atrial flutter is projected to reach over USD 1.7 billion by the end of 2032. Atrial flutter is a condition that occurs due to changes in the electrical system of the heart, caused by health conditions such as hypertension. According to the World Health Organization (WHO), cases of hypertension among individuals aged 30-79 years increased from 650 million to 1.28 billion over the last three decades.
With respect to end-use, the electrophysiology market is segregated into hospitals, ambulatory surgery centers, catheterization/EP laboratories, and others. The ambulatory surgery centers segment accounted for a revenue share of more than USD 180 million in 2022. Due to accessibility to advanced medical facilities, patients increasingly prefer ambulatory units for single-day cardiovascular surgeries. Ambulatory surgery centers also provide best-in-class healthcare at an affordable rate.
Asia Pacific electrophysiology market is poised to exceed USD 3.9 billion by the end of 2032. Increasing public and private funding encouraging awareness initiatives pertaining to cardiovascular diseases will complement industry expansion across APAC. Rapidly pacing medical tourism across APAC countries such as China, and India will offer lucrative business prospects over the projected timeframe.